A therapeutic drug monitoring panel measures the amount of certain medicines in the blood so the dose can be adjusted safely. It is used most often for drugs that have a narrow therapeutic range, meaning the helpful dose and harmful dose are close together. A level that is too low may fail to control seizures, infection, rejection risk, heart rhythm problems, or mood symptoms. A level that is too high can cause toxicity, sometimes before symptoms are obvious.
TDM results are not interpreted like many routine blood tests. The timing of the blood draw, the last dose, kidney and liver function, age, drug interactions, albumin level, and symptoms all change what the number means. A “therapeutic” result may still be wrong for one person, while a slightly outside-range result may be expected during dose changes or special treatment plans.
- A TDM panel measures medication concentration, usually in serum, plasma, or whole blood, to guide safe dosing.
- The most common monitored drugs include lithium, digoxin, phenytoin, carbamazepine, valproic acid, vancomycin, aminoglycosides, tacrolimus, cyclosporine, sirolimus, and methotrexate.
- A trough level is drawn just before the next dose; a peak level is drawn after a dose when the drug is expected to be near its highest concentration.
- Abnormal results can mean underdosing, toxicity risk, missed doses, drug interactions, kidney or liver clearance problems, or a mistimed blood draw.
- Urgent follow-up is important when high levels occur with confusion, fainting, severe tremor, seizures, irregular heartbeat, severe vomiting, or reduced urination.
Table of Contents
- What a TDM Panel Measures
- Why Medication Levels Are Ordered
- Peak, Trough, Random, and Timed Levels
- Common Medications and Therapeutic Ranges
- How to Interpret Low, High, and Toxic Results
- Factors That Change TDM Results
- What Happens After an Abnormal Result
- Questions to Ask About Your Results
What a TDM Panel Measures
A therapeutic drug monitoring panel measures how much of a specific medication is circulating in the blood at a specific time. The result is usually reported as a concentration, such as mcg/mL, ng/mL, mg/L, mEq/L, or mmol/L. The exact unit depends on the medication.
The test may measure one drug, several drugs, or a medication plus related safety markers. For example, lithium monitoring often includes kidney and thyroid testing over time. Digoxin interpretation often includes potassium and kidney function. Vancomycin dosing is often paired with creatinine and sometimes pharmacy-calculated exposure estimates.
TDM is most useful when three things are true: the drug level relates reasonably well to benefit or harm, the drug has meaningful person-to-person variation, and symptoms alone are not enough to guide dosing safely. A person taking a standard dose can still have a high level if the kidneys clear the drug slowly, if another medicine blocks metabolism, or if dehydration concentrates the drug in the body.
The blood compartment also matters. Many drug levels are measured in serum or plasma, but tacrolimus and cyclosporine are usually measured in whole blood because they distribute heavily into red blood cells. Some drugs are measured as total concentration, while others may also have a free level. The free level is the unbound portion that can act on tissues. This is especially important for highly protein-bound drugs such as phenytoin and valproic acid.
TDM does not replace clinical judgment. It adds a number to the full picture: dose, dose schedule, timing, symptoms, kidney function, liver function, albumin, interacting medicines, and the condition being treated.
Why Medication Levels Are Ordered
Medication levels are ordered when the dose needs closer control than symptoms can provide. This is common when a medicine can become ineffective at low levels and dangerous at high levels.
Common reasons include:
- Checking whether a dose has reached the expected range after starting or changing treatment
- Looking for toxicity when symptoms appear
- Confirming whether a person is absorbing or taking the medication as expected
- Adjusting the dose after kidney or liver function changes
- Managing drug interactions
- Monitoring treatment during pregnancy, critical illness, dialysis, transplant care, or major weight changes
- Checking antibiotic exposure during severe infection
- Following high-dose methotrexate clearance after cancer treatment protocols
Some TDM tests are ordered routinely. Others are ordered only when there is a problem. For example, a person on stable carbamazepine may need periodic levels or levels after a dose change, while a patient receiving high-dose vancomycin in the hospital may need more structured monitoring because the risk of kidney injury rises with excessive exposure.
Medication levels often fit together with other blood tests. A high digoxin level is more concerning when potassium is low or kidney function has worsened. A lithium level needs context from creatinine, sodium balance, hydration, and symptoms. A phenytoin level may need albumin because low albumin can make the active free drug higher than the total level suggests.
TDM is especially important when symptoms overlap with the disease being treated. Dizziness, confusion, nausea, tremor, and fatigue may come from the medication, the illness, dehydration, infection, or another drug. The level helps narrow the cause.
For related patterns, lithium results often need to be interpreted with kidney function during lithium monitoring, while digoxin results often need potassium context because digoxin and potassium together shape toxicity risk.
Peak, Trough, Random, and Timed Levels
The timing of the blood draw can change the result as much as the dose itself. A number without timing may be hard to use.
Trough level
A trough level is drawn just before the next dose, when the medication is expected to be at or near its lowest concentration. Troughs are common for many steady-state medicines because they are easier to standardize and often relate to toxicity risk or minimum exposure.
Examples include tacrolimus troughs before the morning dose, carbamazepine troughs before the next scheduled dose, and traditional vancomycin troughs before the next infusion. For some drugs, a trough is not just convenient; it is the expected specimen timing for interpretation.
Peak level
A peak level is drawn after a dose, when the medication is expected to be near its highest concentration. Peak timing depends on the drug, route, and infusion length. Aminoglycoside antibiotics are classic examples because peak levels relate to bacterial killing, while trough levels relate more to accumulation and toxicity.
A peak drawn too early may catch the distribution phase and look falsely high. A peak drawn too late may look falsely low. For this reason, the lab result should be matched to the exact collection instructions.
Random level
A random level is drawn without strict peak or trough timing. Random levels can still be useful in emergencies, suspected toxicity, missed-dose situations, kidney failure, dialysis, or when the exact dosing history is unknown. They are less useful for routine dose adjustment unless the clinician can match the result to the time since the last dose.
Timed level
Some drug levels must be interpreted by exact hours after ingestion or infusion. Acetaminophen overdose testing uses a timed level plotted against time after ingestion. High-dose methotrexate monitoring follows levels at set intervals such as 24, 48, and 72 hours, depending on the treatment protocol.
Vancomycin has also shifted toward exposure-based monitoring in many hospital settings. Instead of relying only on a trough, clinicians may estimate the area under the concentration-time curve, often called AUC. This is why vancomycin trough and AUC monitoring may appear together in hospital reports.
Common Medications and Therapeutic Ranges
Therapeutic ranges are general reference targets, not personal dose instructions. Laboratories, hospitals, transplant programs, and specialties may use different ranges based on the medication, assay, diagnosis, infection severity, organ transplant type, time after transplant, age, pregnancy status, kidney function, and other risk factors.
| Medication or group | Common monitoring approach | Typical reference or target range | Common concern if high |
|---|---|---|---|
| Lithium | 12-hour trough, usually after steady state | Often about 0.6–1.2 mEq/L; many maintenance targets are narrower | Tremor, vomiting, confusion, kidney injury, seizures |
| Digoxin | Level at least 6–8 hours after dose, often trough-like | Often about 0.5–0.9 ng/mL for heart failure; higher ranges may be used for some arrhythmia care | Nausea, visual changes, slow or irregular rhythm, dangerous arrhythmias |
| Phenytoin | Total level, sometimes free level | Total: about 10–20 mcg/mL; free: about 1–2 mcg/mL | Nystagmus, ataxia, slurred speech, confusion |
| Carbamazepine | Usually trough | About 4–12 mcg/mL | Dizziness, double vision, low sodium, liver or blood cell problems |
| Valproic acid | Total level, sometimes free level | Often about 50–100 mcg/mL for seizures; some uses allow up to about 125 mcg/mL | Tremor, sedation, low platelets, liver injury, high ammonia |
| Phenobarbital | Usually trough or steady-state level | About 10–40 mcg/mL | Excess sedation, poor coordination, slowed breathing at very high levels |
| Theophylline | Timed level based on formulation and dosing | Often about 10–20 mcg/mL, though lower targets may be used | Nausea, tremor, fast heart rate, seizures, arrhythmias |
| Vancomycin | AUC-based monitoring for many serious MRSA infections; troughs may still be reported | AUC/MIC target often 400–600 when MIC is assumed to be 1 mg/L | Kidney injury, excessive exposure |
| Gentamicin and other aminoglycosides | Peak and trough or extended-interval monitoring | Depends strongly on infection type and dosing strategy | Kidney injury, hearing or balance toxicity |
| Tacrolimus | Whole-blood trough | Often about 5–15 ng/mL, but target varies by transplant type and time after transplant | Kidney injury, tremor, high potassium, infection risk |
| Cyclosporine | Whole-blood trough or 2-hour post-dose level in some protocols | Highly protocol-dependent | Kidney injury, high blood pressure, tremor, gum overgrowth |
| Sirolimus | Whole-blood trough | Often about 5–15 ng/mL, depending on regimen | Mouth ulcers, high lipids, low blood counts, delayed wound healing |
| Methotrexate, high-dose therapy | Timed levels after infusion | Protocol-specific clearance thresholds rather than one therapeutic range | Kidney injury, mucositis, marrow suppression, delayed clearance |
Seizure medication levels are a common reason for TDM because missed doses, pregnancy, interacting medicines, liver disease, and protein binding can all shift the result. A combined discussion of carbamazepine, phenytoin, and valproic acid levels can be especially useful when comparing seizure medication patterns.
Transplant drug ranges are among the most individualized. Tacrolimus targets may be higher soon after transplant and lower later, but the exact range comes from the transplant team. Results should be interpreted with tacrolimus and creatinine monitoring because kidney effects can appear even when the blood level is near the expected range.
How to Interpret Low, High, and Toxic Results
A low medication level usually means the amount of drug in the blood is below the expected range for the treatment plan. It can happen because the dose is too low, doses were missed, the blood was drawn late, the medication was not absorbed well, or another drug increased clearance. For antibiotics, a low level can raise concern for treatment failure. For antiseizure medicines, it can raise seizure risk. For transplant medicines, it can increase rejection risk.
A high level means the concentration is above the expected range. It does not always mean poisoning, but it raises concern for side effects and often prompts a review of dose timing, kidney or liver function, interacting drugs, and symptoms. A high trough is especially important because it can show accumulation between doses.
A toxic level means the concentration is high enough that harm is likely or already present. Toxic thresholds vary by medication and person. Some people develop symptoms within the upper therapeutic range, especially older adults or people with kidney disease. Others may tolerate a modestly elevated level for a short time under close supervision.
Symptoms matter as much as the number. A lithium level of 1.4 mEq/L with severe tremor, vomiting, and confusion needs urgent attention. A digoxin level that is only mildly high may be dangerous when potassium is low or kidney function has dropped. A phenytoin total level may look acceptable while the free level is high in a person with low albumin.
| Pattern | Possible meaning | Typical next check |
|---|---|---|
| Low trough | Dose may be too low, doses may be missed, clearance may be faster than expected, or the sample may have been drawn too late | Dose history, timing, adherence, interacting drugs |
| High trough | Drug may be accumulating between doses | Kidney or liver function, dose interval, recent dose change |
| High peak with acceptable trough | Peak-related side effects may occur, depending on drug | Infusion timing, dose size, symptom timing |
| Normal total level with toxicity symptoms | Free drug may be high, symptoms may be from another cause, or the range may not fit the person | Free level, albumin, electrolytes, other medicines |
| Unexpectedly low level despite high dose | Missed doses, poor absorption, fast metabolism, drug interaction, or lab/timing issue | Medication schedule, pharmacy refill pattern, repeat timed level |
| Rising level after kidney function worsens | Reduced clearance and accumulation | Creatinine, eGFR, urine output, dose hold or adjustment plan |
A single level rarely tells the whole story. The trend is often more useful: whether the level is rising, falling, stable, or delayed in clearing after a dose hold.
Factors That Change TDM Results
Many TDM surprises come from timing or body chemistry rather than the prescribed dose.
The most common issue is a mistimed blood draw. A trough collected after the morning dose may look falsely high. A peak drawn before full distribution may overestimate the useful peak. A random level may be misread as a trough if the lab slip does not include the last dose time.
Kidney function strongly affects drugs cleared by the kidneys, including lithium, digoxin, vancomycin, aminoglycosides, and methotrexate. Dehydration, vomiting, diarrhea, diuretics, nonsteroidal anti-inflammatory drugs, ACE inhibitors, angiotensin receptor blockers, and acute illness can all change clearance. Patterns that involve creatinine and eGFR are often reviewed alongside a kidney function blood test panel.
Liver function affects many antiseizure medications and theophylline. Enzyme-inducing drugs can lower levels of other medications by speeding metabolism. Enzyme inhibitors can raise levels by slowing metabolism. Carbamazepine is especially complex because it can increase its own metabolism over time, a process called autoinduction.
Protein binding can make total levels misleading. Phenytoin and valproic acid bind to albumin. When albumin is low, the free active fraction may rise even if the total result looks normal. Kidney failure, critical illness, pregnancy, older age, and certain drug interactions can also change free drug levels. In these situations, a free phenytoin or free valproic acid level may be more useful than a total level.
Electrolytes can change toxicity risk. Low potassium and low magnesium increase the risk of digoxin-related arrhythmias. High potassium may appear with serious digoxin toxicity or with tacrolimus-related kidney effects. Potassium patterns are often interpreted with a potassium and creatinine risk review.
Pregnancy can lower some drug levels by increasing blood volume, kidney filtration, and liver metabolism. This is well known with several antiseizure medicines. Older age can do the opposite by reducing clearance and increasing sensitivity to side effects.
Assay differences also matter. Some tests measure parent drug only, while others may cross-react with metabolites. Whole-blood and serum results are not interchangeable. A transplant drug target from one program should not be applied blindly to another assay or protocol.
What Happens After an Abnormal Result
An abnormal TDM result usually leads to a structured review before the dose is changed. The clinician checks the result, the timing, the dose schedule, the last dose, recent missed doses, new medicines, kidney or liver function, and symptoms.
For a low level, the response may be to increase the dose, shorten the dosing interval, check adherence, repeat the level at the correct time, or wait until steady state if the medicine was recently started. Steady state usually means the drug concentration has had enough time to stabilize after a dose change. For many drugs, this takes about 4–5 half-lives, but the actual time varies widely.
For a high level without symptoms, the clinician may hold one or more doses, reduce the dose, lengthen the interval, or repeat a level. For a high level with symptoms, the response may be urgent. Some medicines have specific reversal or rescue treatments. Severe digoxin toxicity may be treated with digoxin-specific antibody fragments. High-dose methotrexate delayed clearance may require leucovorin rescue and aggressive supportive care. Severe lithium poisoning may require emergency care and sometimes dialysis.
Antibiotic monitoring often involves pharmacy dosing support. Vancomycin and aminoglycoside levels may be used to calculate a new dose and interval rather than simply labeling the result low or high. For serious MRSA infections, vancomycin exposure targets are commonly tied to AUC because trough-only dosing can expose some patients to excessive levels.
Transplant medication changes should be handled by the transplant team or a clinician familiar with the protocol. A low tacrolimus level shortly after transplant may carry different risk than the same level years later. A high level may increase kidney and neurologic toxicity, but lowering it too much can raise rejection risk.
The safest response is never to change or stop a monitored medication without instructions unless a clinician has already given a specific plan for certain symptoms or results.
Questions to Ask About Your Results
TDM results are easier to understand when the report is tied to the treatment plan. Helpful questions include:
- Was this intended to be a trough, peak, random, or timed level?
- Was the blood drawn at the correct time after my last dose?
- What target range is being used for my condition?
- Is my result being interpreted as total drug, free drug, serum, plasma, or whole blood?
- Do my kidney function, liver tests, albumin, sodium, potassium, or magnesium change the interpretation?
- Could any new medication, supplement, antibiotic, antifungal, heart drug, seizure drug, or pain reliever affect this level?
- Should the dose change now, or should the level be repeated first?
- When should the next level be checked?
- What symptoms should make me seek urgent care?
Bring the medication bottle, dose schedule, and exact time of the last dose when possible. For hospital or infusion medications, the infusion start and stop times matter. For once-daily morning medications, some tests are best drawn before the dose. For lithium, many clinicians use a 12-hour post-dose level, often drawn the morning after an evening dose.
Several warning symptoms deserve prompt medical advice when they occur with a high or possibly high drug level: fainting, severe dizziness, confusion, severe tremor, new trouble walking, persistent vomiting, seizures, yellowing of the skin or eyes, very slow or irregular heartbeat, shortness of breath, reduced urination, severe weakness, or unusual bleeding.
References
- The Steps to Therapeutic Drug Monitoring: A Structured Approach Illustrated With Imatinib 2020 (Review)
- Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists 2020 (Guideline)
- What is the optimal serum level for lithium in the maintenance treatment of bipolar disorder? A systematic review and recommendations from the ISBD/IGSLI Task Force on treatment with lithium 2019 (Systematic Review)
- TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians 2018 (Guideline)
- Therapeutic Drug Monitoring of Immunosuppressant Drugs 2019 (Review)
Disclaimer
Therapeutic drug monitoring results should be interpreted by a licensed clinician who knows the medication dose, timing, diagnosis, symptoms, and other lab results. Do not change, skip, or restart a monitored medication based only on a lab number unless your clinician has given you specific instructions. Seek urgent care for severe symptoms such as confusion, fainting, seizures, severe vomiting, irregular heartbeat, or markedly reduced urination.
